Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600276'
s Days Inventory Range Over the Past 10 Years
Min: 140.71 Med: 194.19 Max: 254.03
Current: 224.53
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest Days Inventory was 254.03. The lowest was 140.71. And the median was 194.19.
SHSE:600276's Days Inventory is ranked worse than 70.86% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs SHSE:600276: 224.53
Inventory Turnover measures how fast the company turns over its inventory within a year.
Jiangsu Hengrui Pharmaceuticals Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.38.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jiangsu Hengrui Pharmaceuticals Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.35.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Jiangsu Hengrui Pharmaceuticals Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jiangsu Hengrui Pharmaceuticals Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Jiangsu Hengrui Pharmaceuticals Co Days Inventory Related Terms
Jiangsu Hengrui Pharmaceuticals Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Days Inventory Chart
SHSE:600276 vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Days Inventory of 241.08 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 24% above median its historical median of 194.19. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Days Inventory has ranged from 140.71 to 254.03. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #654 out of 923 companies in the Drug Manufacturers industry, placing it in the top 70.9%.
Is Jiangsu Hengrui Pharmaceuticals Co's Days Inventory too high?
Jiangsu Hengrui Pharmaceuticals Co's current Days Inventory of 241.08 is 24% above median its 10-year median of 194.19. Over the past 10 years, this metric has ranged from a low of 140.71 to a high of 254.03. The Drug Manufacturers industry median Days Inventory is 164.38. Jiangsu Hengrui Pharmaceuticals Co's value of 241.08 is 46.7% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #654 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #654 out of 923 companies for Days Inventory. This places Jiangsu Hengrui Pharmaceuticals Co in the lower half of its industry. The industry median Days Inventory is 164.38. Jiangsu Hengrui Pharmaceuticals Co's value of 241.08 is 46.7% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Days Inventory has ranged from 140.71 to 254.03 over the past decade. While the company's 10-year median is 194.19 vs. the industry median of 164.38, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Days Inventory of 241.08 is 46.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Days Inventory is 241.08, which is 24% above median its own 10-year median of 194.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.76, compared to a current price of ¥53.19 — trading 12.5% below its estimated fair value. The current Days Inventory is 241.08, which is 24% above median its 10-year median of 194.19 and 46.7% above the Drug Manufacturers industry median of 164.38. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Days Inventory is 241.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥53.19 is trading 12.5% below its estimated GF Value™ of ¥60.76.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
Days Inventory: 241.08 (24% above median its 10-year median of 194.19)
GF Value™: ¥60.76 vs. price of ¥53.19 (12.5% below fair value)
Industry Position: 46.7% above the Drug Manufacturers median (#654 of 923)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score
Get the complete analysis for SHSE:600276
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
